Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed invasive breast cancer~  * Clinical evidence of metastatic disease~    * No bone metastases as the only evidence of metastasis~* Measurable disease~  * At least 1 lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan~    * Lesions on chest x-ray allowed provided they are clearly defined and surrounded by aerated lung~ * Clincal lesions only considered measurable when they are superficial (e.g., skin nodules or palpable lymph nodes)~ * Target lesion must not have been exposed to prior radiotherapy unless disease has progressed since completion of radiotherapy~ * The following are not considered measurable disease:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural or pericardial effusion~   * Inflammatory breast disease~   * Lymphangitis cutis or pulmonis~   * Abdominal masses that are not confirmed and followed by imaging techniques~   * Cystic lesions~* No HER2/neu-positive tumors by immunohistochemistry or amplified fluorescence in situ hybridization unless disease has progressed after trastuzumab (Herceptin®)-containing therapy alone or with antiestrogen hormonal therapy for metastatic disease OR trastuzumab is contraindicated~* Prior breast cancer allowed~* No prior or active brain metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Male or female~Menopausal status~* Not specified~Performance status~* ECOG 0-1~Life expectancy~* At least 3 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* No bleeding diathesis or uncontrolled coagulopathy~Hepatic~* Bilirubin normal~* Meets 1 of the following criteria:~  * AST and ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)~ * AST and ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN~ * AST and ALT ≤ 5 times ULN AND alkaline phosphatase normal~Renal~* Creatinine clearance ≥ 30 mL/min~* No proteinuria OR~* Protein \< 1 g by 24-hour urine collection~* No nephrotic syndrome~Cardiovascular~* No uncontrolled hypertension (i.e., blood pressure \> 160/90 mm Hg on ≥ 2 different observations ≥ 5 minutes apart)~  * Blood pressure \< 140/90 mm Hg on ≥ 3 different observations over ≥ 14 days, for patients who recently began or adjusted anti-hypertensive medication~* No atrial or venous thrombosis within the past month~* No clinically significant heart disease, including any of the following:~  * Congestive heart failure~ * Symptomatic coronary artery disease~ * Uncontrolled cardiac arrhythmias~ * Unstable angina~* No myocardial infarction within the past 12 months~* No history of cerebrovascular accident~Pulmonary~* No hemoptysis within the past 6 months~Gastrointestinal~* No lack of physical integrity of the upper gastrointestinal tract~* No malabsorption syndrome~* Able to receive oral medication~Other~* No other stage III or IV invasive malignancy requiring treatment within the past 5 years~* No pre-existing peripheral neuropathy \> grade 1~* No history of allergy or hypersensitivity to study drugs, agents that are chemically similar to study drugs, or drugs that contain polysorbate 80~* No prior severe reaction to fluoropyrimidines~* No known hypersensitivity to fluorouracil~* No known dihydropyrimidine dehydrogenase deficiency~* No active infection~* No significant medical condition that would preclude study participation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 30 days after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* No other concurrent biologic therapy~Chemotherapy~* Prior adjuvant or neoadjuvant chemotherapy allowed for primary disease~* No prior chemotherapy for metastatic disease~* More than 4 weeks since prior cytotoxic chemotherapy~* More than 6 months since prior taxanes (e.g., docetaxel or paclitaxel)~* No other concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* Prior antiestrogen hormonal therapy allowed in the adjuvant or metastatic setting~Radiotherapy~* See Disease Characteristics~* More than 4 weeks since prior radiotherapy to a target lesion~  * Prior single-dose palliative radiotherapy allowed within the past 4 weeks~* No concurrent radiotherapy~Surgery~* More than 4 weeks since prior major surgery~Other~* More than 2 weeks since prior aspirin, anticoagulants, or thrombolytic agents~  * Concurrent low-dose warfarin (1 mg/day) to maintain patency of vascular access device allowed~* More than 4 weeks since prior investigational agents~* No concurrent aspirin, anticoagulants, or thrombolytic agents~* No concurrent participation in another clinical trial involving investigational agents or procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- docetaxel + bevacizumab + capecitabine (Type: EXPERIMENTAL): Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).